Search results for: Kenneth Arrow
Filter search results
Brittany Darrow
2 October 2024
Brittany Darrow joined OHE as a Graduate Economist in October 2024. She holds a Master of Science in Economics and Policy from King’s College London and a BA in Economics…
OHE Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?
14 June 2017, 11:00pm
…Studies. She has been awarded the Kenneth J. Arrow Prize in Health Economics from the International Health Economics Association, for her work on the links between economic status and health…
Invitation to OHE’s Annual Lecture 2017: Why are Mortality Rates Rising for Middle-Aged White Non-Hispanic Americans? Could it Happen in Europe?
12 May 2017
…Studies. She has been awarded the Kenneth J. Arrow Prize in Health Economics from the International Health Economics Association, for her work on the links between economic status and health…
Economic Aspects of Non-Hodgkin’s Lymphoma
1 July 1998
…they are all cancerous growths of lymphocytes. These are cells of the immune system which are produced from bone marrow and are located within the lymph glands. Lymphocytes are designed…
OHE Lunchtime Seminar: Management in the NHS
4 September 2017, 11:00pm
…Reenan were awarded the International Health Economics Association Arrow Award for the best paper in health economics worldwide for their paper “Can Pay Regulation Kill?” JPE 118(21):222-273. In 2016 Carol…
OHE at ISPOR Europe 2026
8 November 2026, 12:00am
Timetable 9 November 2026 Title Name Time Type One Policy, Many Responses: Mapping European Strategies to U.S. Most-Favoured Nation Pricing Brittany Darrow 10:30-13:30 Poster Session 1 Unlocking The Value of…
Beyond opportunity cost: what are health systems for? The UK–US pharmaceutical agreement and the limits of QALY maximisation
23 October 2026
…term of the trade deal, even in very narrow balance of trade terms this represents good value. Once we consider the wider economic benefits the UK gets from a thriving…
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
23 September 2026
…and a growing ‘biosimilar void’. The dominant policy response has been narrow, focusing on biosimilar value as a cost-saving opportunity in already-funded populations. This report argues that this framing misses…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
…phases, and (3) using new data sources to estimate lifetime drug revenues. Despite these refinements, significant limitations remain. The model: Relies on a narrow conception of biopharmaceutical innovation that continues…